11.6 C
New York
19.7 C
Los Angeles
12.5 C
Chicago
15.6 C
Houston

A new paradigm of acne treatment, the commercialization of “antimicrobial peptide C4,” an antimicrobial substance that overcomes tolerance and side effects

Must read

Justin Maak
Justin Maakhttps://www.resticmagazine.com
I cover business topics for Restic Magazine. I have a master’s degree in journalism from Columbia University and live in New York City. I’ve previously reported for USA Today, Business Insider, The San Francisco Business Times and San Jose Inside.

Skincare and research communities are in awe of the latest model of Antimicrobial Peptide C4 discovered by Celltem which has already shown great promise in changing acne treatment capability and efficacy across the board.

As it stands, there are consistent issues involving side effects and recurring ailments because of existing antimicrobial acne treatments. The team at Celltem have tirelessly researched and developed their Antimicrobial Peptide C4 with innovation at the forefront and a goal of targeting side effects and antibiotic resistance.

This new paradigm represents a leap forward for acne sufferers as current antimicrobial acne remedies and antibiotics have been known to elicit or propagate side effects in users that can range from redness and irritation, all the way to contact dermatitis and even fever/vomiting.

The Celltem Antimicrobial Peptide C4 addresses these issues effectively – as a result, commercialization viability is apparent.

Antimicrobial Peptide C4 Exhibiting Antimicrobial Activity

Celltem’s Antimicrobial Peptide C4 is derived from milk protein and has already demonstrated an impressive inhibitory effect on pathogenic bacteria on the epidermis including C. Acnes (Cutibacterium acnes). The manner in which the harmful cell membranes are targeted supports the “inhibitory” demarcation.

Celltem Pharm

Pathogenic Bacteria V Beneficial Bacteria 

The crux of the difference between existing forms of antimicrobial-based acne treatments and the Celltem Antimicrobial peptide C4 variant is in the targeting of ‘harmful’ bacterium. The existing treatments have a foible in that they target harmful bacteria as well as good bacteria simultaneously. During antimicrobial action, beneficial bacteria act as a barrier/protector of the skin – the issue with destroying good bacteria is that it leaves the user open to irritation and sensitivities.

Antimicrobial Peptide C4 is formulated to target harmful bacteria only, leaving the good bacteria unaffected and better able to protect the user from irritation. This greatly lowers the risk of adverse side effects and the defence barriers strengthened.

Percent Science’s Commercialization & Viability For The Market

Antimicrobial Peptide C4 is a wildly effective antimicrobial agent, this has led to difficulty in achieving strong market stability and commercialization – until Percent Science entered the fray. The bio-cosmetic brand has managed to commercialize the discovery through its flagship skin care product – doing so with the support of biotechnological metrics and testing parameters. These include substance stabilization testing, in-vitro efficacy testing, cytotoxicity testing, TDDS delivery systems and human application testing.

- Advertisement -spot_img

More articles

- Advertisement -spot_img

Latest article